( (edema) inmany patients. Edema is a d...)Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM),Health

(edema) in many patients. Edema is a debilitating symptom in many brain cancer patients and is currently treated with steroid drugs, which can carry their own debilitating side effects. Based on the first 16 patients a steroid-sparing effect was demonstrated in most patients and was associated with the normalization of tumor vessels. This normalization might help to secure delivery and improve effectiveness of other therapeutic techniques such as chemotherapy drugs and radiation therapy," said Dr. Batchelor.

"The prognosis for recurrent glioblastoma patients is poor," commented AstraZeneca's Dr. Nick Botwood, Global Medical Director for cediranib. "These are promising Phase II results and discussions are ongoing with Dr. Tracy Batchelor and his group regarding a confirmatory study in recurrent glioblastoma."

Cediranib Phase II study in metastatic renal cell carcinoma (RCC)

Another ongoing NCI sponsored cediranib Phase II study presented at ASCO 2007 by investigators from the Princess Margaret Hospital in Toronto, looked at cediranib in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC).(3)

Twenty-seven patients receiving cediranib as monotherapy were able to be evaluated for response with a response rate of 33 percent (9 out of 27 patients) and tumor control rates of 66.7 percent (18 out of 27 patients).(3) The most common toxicities were fatigue, hypertension, diarrhea, and voice alteration.

"Renal cell carcinoma is a chemoresistant disease which has traditionally been difficult to treat, resulting in poor prognosis for patients hence these early data are encouraging," commented Professor S. Sridhar of the Princess Margaret Hospital Phase II Consortium, Toronto, Canada.

These results support another cediranib publication of RCC patients presented at ASCO 2007.(4) In addition, an ongoing AstraZeneca sponsored Phase II, randomized study is currently investigating the efficacy of cediranib i
'"/>

Page: 1 2 3 4
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia